JAK1 and breast carcinoma: In the tumor microenvironment of breast cancer and lung cancer, Di Huang et al. examined that the JAK1-STAT1 signaling pathway in activated T cells upregulates the expression of NKILA lncRNA and inhibits NF-κB activity, thus leading to sensitivity of tumor-specific cytotoxic T lymphocytes (CTLs) and type 1 helper T (Th1) cells to activation-induced cell death (AICD) 60.